1074 related articles for article (PubMed ID: 34483336)
1. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy.
Parums DV
Med Sci Monit; 2021 Sep; 27():e934625. PubMed ID: 34483336
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
3. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021.
Dooling K; Gargano JW; Moulia D; Wallace M; Rosenblum HG; Blain AE; Hadler SC; Plumb ID; Moline H; Gerstein J; Collins JP; Godfrey M; Campos-Outcalt D; Morgan RL; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1344-1348. PubMed ID: 34555007
[TBL] [Abstract][Full Text] [Related]
4. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021.
Woodworth KR; Moulia D; Collins JP; Hadler SC; Jones JM; Reddy SC; Chamberland M; Campos-Outcalt D; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Mbaeyi S; Dooling K; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(45):1579-1583. PubMed ID: 34758012
[TBL] [Abstract][Full Text] [Related]
5. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.
Wallace M; Woodworth KR; Gargano JW; Scobie HM; Blain AE; Moulia D; Chamberland M; Reisman N; Hadler SC; MacNeil JR; Campos-Outcalt D; Morgan RL; Daley MF; Romero JR; Talbot HK; Lee GM; Bell BP; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):749-752. PubMed ID: 34014913
[TBL] [Abstract][Full Text] [Related]
6. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
Oliver SE; Gargano JW; Marin M; Wallace M; Curran KG; Chamberland M; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S; Romero JR; Talbot HK; Lee GM; Bell BP; Dooling K
MMWR Morb Mortal Wkly Rep; 2020 Dec; 69(50):1922-1924. PubMed ID: 33332292
[TBL] [Abstract][Full Text] [Related]
7. BNT162b2 mRNA COVID-19 Vaccine: First Approval.
Lamb YN
Drugs; 2021 Mar; 81(4):495-501. PubMed ID: 33683637
[TBL] [Abstract][Full Text] [Related]
8. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
9. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
[TBL] [Abstract][Full Text] [Related]
10. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.
Powell J; Piszczatoski CR
Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364
[TBL] [Abstract][Full Text] [Related]
11. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS
AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150
[TBL] [Abstract][Full Text] [Related]
12. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021.
Mbaeyi S; Oliver SE; Collins JP; Godfrey M; Goswami ND; Hadler SC; Jones J; Moline H; Moulia D; Reddy S; Schmit K; Wallace M; Chamberland M; Campos-Outcalt D; Morgan RL; Bell BP; Brooks O; Kotton C; Talbot HK; Lee G; Daley MF; Dooling K
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1545-1552. PubMed ID: 34735422
[TBL] [Abstract][Full Text] [Related]
13. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
[TBL] [Abstract][Full Text] [Related]
14. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
[TBL] [Abstract][Full Text] [Related]
15. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021.
Hause AM; Gee J; Baggs J; Abara WE; Marquez P; Thompson D; Su JR; Licata C; Rosenblum HG; Myers TR; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(31):1053-1058. PubMed ID: 34351881
[TBL] [Abstract][Full Text] [Related]
17. Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine.
Tano E; San Martin S; Girgis S; Martinez-Fernandez Y; Sanchez Vegas C
J Pediatric Infect Dis Soc; 2021 Nov; 10(10):962-966. PubMed ID: 34319393
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
[TBL] [Abstract][Full Text] [Related]
20. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
;
MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
